Are there new therapies to manage my rheumatoid arthritis?

Question

Hello doctor,

I am 44, with rheumatoid arthritis for seven years, but it has been progressing rapidly despite multiple medication changes. My hands are so deformed and painful that I cannot open jars, write, or button clothes anymore. Morning stiffness lasts for hours, and pain is constant even with prescription medications. I have tried Methotrexate, Sulfasalazine, and two biologics, but they do not work or cause terrible side effects like recurrent infections.

The latest biologic gave me severe flu symptoms, and I got shingles twice in six months. My rheumatologist wants to prescribe another medicine, but I am scared. X-rays show joint erosion progressing in my hands and feet. Work as a mechanic is becoming impossible, and walking is difficult. Fatigue is overwhelming, and I feel like I am aging rapidly.

Are there newer therapies that work better for both severe skin and joint involvement?
I need inflammation control without constant infections.

Kindly help.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

Your history suggests severe progressive rheumatoid arthritis with ongoing structural damage despite multiple conventional and biologic therapies. That is very good to know you have a good understanding of the medication you are using. When Methotrexate, Sulfasalazine, and two biologics have failed or caused significant infections, it is appropriate to reassess the treatment strategy rather than simply cycling through another TNF inhibitor.

There are newer targeted options called JAK inhibitors, such as:

Tofacitinib.
Upadacitinib.
Baricitinib.

These work inside the inflammatory signaling pathway rather than blocking a single external cytokine, and some patients who do not respond to TNF inhibitors achieve good control with these agents.

Other non-TNF biologics, such as Abatacept, which modulates T cell activation, or Rituximab, which targets B cells, may also be considered, particularly in patients with recurrent infections, because their infection profiles differ from TNF blockers.

Shingles recurrence suggests immune suppression vulnerability, and vaccination status should be reviewed before further therapy adjustments. Persistent erosions on imaging indicate uncontrolled inflammation, so achieving low disease activity or remission is critical to prevent further disability. Fatigue is often driven by systemic inflammation and improves when disease control is achieved.

Given your functional decline and occupational limitations, an urgent comprehensive review with your rheumatologist is warranted to evaluate alternative mechanisms of action, optimize infection prevention strategies, and possibly involve a multidisciplinary team, including pain management and physical therapy. The goal remains tight inflammation control while minimizing infection risk and preserving long-term joint function and quality of life.

I hope you are satisfied with my answer. For further queries, you can consult me at iCliniq.

Thank you.